Epimutational profile of hematologic malignancies as attractive target for new epigenetic therapies

Elisabetta Fratta, Barbara Montico, Aurora Rizzo, Francesca Colizzi, Luca Sigalotti, Riccardo Dolcetti

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

In recent years, recurrent somatic mutations in epigenetic regulators have been identified in patients with hematological malignancies. Furthermore, chromosomal translocations in which the fusion protein partners are themselves epigenetic regulators or where epigenetic regulators are recruited/targeted by oncogenic fusion proteins have also been described. Evidence has accumulated showing that "epigenetic drugs" are likely to provide clinical benefits in several hematological malignancies, granting their approval for the treatment of myelodysplastic syndromes and cutaneous T-cell lymphomas. A large number of pre-clinical and clinical trials evaluating epigenetic drugs alone or in combination therapies are ongoing. The aim of this review is to provide a comprehensive summary of known epigenetic alterations and of the current use of epigenetic drugs for the treatment of hematological malignancies.

Original languageEnglish
Pages (from-to)57327-57350
Number of pages24
JournalOncotarget
Volume7
Issue number35
DOIs
Publication statusPublished - 2016

Fingerprint

Hematologic Neoplasms
Epigenomics
Therapeutics
Pharmaceutical Preparations
Cutaneous T-Cell Lymphoma
Genetic Translocation
Myelodysplastic Syndromes
Proteins
Clinical Trials
Mutation

Keywords

  • 5-aza-2'-deoxycytidine
  • Azacytidine
  • DNA methylation
  • Hematological malignancies
  • Histone modifications

ASJC Scopus subject areas

  • Oncology

Cite this

Epimutational profile of hematologic malignancies as attractive target for new epigenetic therapies. / Fratta, Elisabetta; Montico, Barbara; Rizzo, Aurora; Colizzi, Francesca; Sigalotti, Luca; Dolcetti, Riccardo.

In: Oncotarget, Vol. 7, No. 35, 2016, p. 57327-57350.

Research output: Contribution to journalArticle

Fratta, Elisabetta ; Montico, Barbara ; Rizzo, Aurora ; Colizzi, Francesca ; Sigalotti, Luca ; Dolcetti, Riccardo. / Epimutational profile of hematologic malignancies as attractive target for new epigenetic therapies. In: Oncotarget. 2016 ; Vol. 7, No. 35. pp. 57327-57350.
@article{530f608b4f7642238510fc2ef7870d58,
title = "Epimutational profile of hematologic malignancies as attractive target for new epigenetic therapies",
abstract = "In recent years, recurrent somatic mutations in epigenetic regulators have been identified in patients with hematological malignancies. Furthermore, chromosomal translocations in which the fusion protein partners are themselves epigenetic regulators or where epigenetic regulators are recruited/targeted by oncogenic fusion proteins have also been described. Evidence has accumulated showing that {"}epigenetic drugs{"} are likely to provide clinical benefits in several hematological malignancies, granting their approval for the treatment of myelodysplastic syndromes and cutaneous T-cell lymphomas. A large number of pre-clinical and clinical trials evaluating epigenetic drugs alone or in combination therapies are ongoing. The aim of this review is to provide a comprehensive summary of known epigenetic alterations and of the current use of epigenetic drugs for the treatment of hematological malignancies.",
keywords = "5-aza-2'-deoxycytidine, Azacytidine, DNA methylation, Hematological malignancies, Histone modifications",
author = "Elisabetta Fratta and Barbara Montico and Aurora Rizzo and Francesca Colizzi and Luca Sigalotti and Riccardo Dolcetti",
year = "2016",
doi = "10.18632/oncotarget.10033",
language = "English",
volume = "7",
pages = "57327--57350",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "35",

}

TY - JOUR

T1 - Epimutational profile of hematologic malignancies as attractive target for new epigenetic therapies

AU - Fratta, Elisabetta

AU - Montico, Barbara

AU - Rizzo, Aurora

AU - Colizzi, Francesca

AU - Sigalotti, Luca

AU - Dolcetti, Riccardo

PY - 2016

Y1 - 2016

N2 - In recent years, recurrent somatic mutations in epigenetic regulators have been identified in patients with hematological malignancies. Furthermore, chromosomal translocations in which the fusion protein partners are themselves epigenetic regulators or where epigenetic regulators are recruited/targeted by oncogenic fusion proteins have also been described. Evidence has accumulated showing that "epigenetic drugs" are likely to provide clinical benefits in several hematological malignancies, granting their approval for the treatment of myelodysplastic syndromes and cutaneous T-cell lymphomas. A large number of pre-clinical and clinical trials evaluating epigenetic drugs alone or in combination therapies are ongoing. The aim of this review is to provide a comprehensive summary of known epigenetic alterations and of the current use of epigenetic drugs for the treatment of hematological malignancies.

AB - In recent years, recurrent somatic mutations in epigenetic regulators have been identified in patients with hematological malignancies. Furthermore, chromosomal translocations in which the fusion protein partners are themselves epigenetic regulators or where epigenetic regulators are recruited/targeted by oncogenic fusion proteins have also been described. Evidence has accumulated showing that "epigenetic drugs" are likely to provide clinical benefits in several hematological malignancies, granting their approval for the treatment of myelodysplastic syndromes and cutaneous T-cell lymphomas. A large number of pre-clinical and clinical trials evaluating epigenetic drugs alone or in combination therapies are ongoing. The aim of this review is to provide a comprehensive summary of known epigenetic alterations and of the current use of epigenetic drugs for the treatment of hematological malignancies.

KW - 5-aza-2'-deoxycytidine

KW - Azacytidine

KW - DNA methylation

KW - Hematological malignancies

KW - Histone modifications

UR - http://www.scopus.com/inward/record.url?scp=84984917796&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84984917796&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.10033

DO - 10.18632/oncotarget.10033

M3 - Article

VL - 7

SP - 57327

EP - 57350

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 35

ER -